These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 7796956)

  • 1. The history of live bacterial vaccines.
    Lindberg AA
    Dev Biol Stand; 1995; 84():211-9. PubMed ID: 7796956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future vaccines against enteric pathogens.
    Levine MM; Edelman R
    Infect Dis Clin North Am; 1990 Mar; 4(1):105-21. PubMed ID: 2155260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuated Salmonella typhi and Shigella as live oral vaccines and as live vectors.
    Levine MM; Galen J; Barry E; Noriega F; Tacket C; Sztein M; Chatfield S; Dougan G; Losonsky G; Kotloff K
    Behring Inst Mitt; 1997 Feb; (98):120-3. PubMed ID: 9382732
    [No Abstract]   [Full Text] [Related]  

  • 5. Recent advances in the development of live, attenuated bacterial vectors.
    Roland KL; Tinge SA; Killeen KP; Kochi SK
    Curr Opin Mol Ther; 2005 Feb; 7(1):62-72. PubMed ID: 15732531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the development of bacterial vector technology.
    Kochi SK; Killeen KP; Ryan US
    Expert Rev Vaccines; 2003 Feb; 2(1):31-43. PubMed ID: 12901595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers.
    Metzger WG; Mansouri E; Kronawitter M; Diescher S; Soerensen M; Hurwitz R; Bumann D; Aebischer T; Von Specht BU; Meyer TF
    Vaccine; 2004 Jun; 22(17-18):2273-7. PubMed ID: 15149786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The development of a bivalent vaccine against diarrhoeal disease.
    Forrest BD
    Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):449-57. PubMed ID: 2464195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Live attenuated Shigella flexneri mutants as vaccine candidates against shigellosis and vectors for antigen delivery.
    Phalipon A; Sansonetti P
    Biologicals; 1995 Jun; 23(2):125-34. PubMed ID: 7546655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR.
    Viret JF; Dietrich G; Favre D
    Vaccine; 2004 Jun; 22(19):2457-69. PubMed ID: 15193410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Live bacterial delivery systems for development of mucosal vaccines.
    Thole JE; van Dalen PJ; Havenith CE; Pouwels PH; Seegers JF; Tielen FD; van der Zee MD; Zegers ND; Shaw M
    Curr Opin Mol Ther; 2000 Feb; 2(1):94-9. PubMed ID: 11249657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacterial mucosal vaccines: Vibrio cholerae as a live attenuated vaccine/vector paradigm.
    Killeen K; Spriggs D; Mekalanos J
    Curr Top Microbiol Immunol; 1999; 236():237-54. PubMed ID: 9893363
    [No Abstract]   [Full Text] [Related]  

  • 13. Live-attenuated Salmonella as a prototype vaccine vector for passenger immunogens in humans: are we there yet?
    Lewis GK
    Expert Rev Vaccines; 2007 Jun; 6(3):431-40. PubMed ID: 17542757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vaccination against the enterobacteria responsible for enteric infections].
    Sansonetti PJ
    Ann Gastroenterol Hepatol (Paris); 1994; 30(2):60-3. PubMed ID: 8210205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of a Salmonella typhimurium vaccine strain expressing Vibrio cholera CT-B and LPS-O antigen.
    Chen D; Ma Q
    Chin J Biotechnol; 1997; 13(1):43-50. PubMed ID: 9376506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vivotif--a 'magic shield' for protection against typhoid fever and delivery of heterologous antigens.
    Gentschev I; Spreng S; Sieber H; Ures J; Mollet F; Collioud A; Pearman J; Griot-Wenk ME; Fensterle J; Rapp UR; Goebel W; Rothen SA; Dietrich G
    Chemotherapy; 2007; 53(3):177-80. PubMed ID: 17347563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors.
    Levine MM; Galen J; Barry E; Noriega F; Chatfield S; Sztein M; Dougan G; Tacket C
    J Biotechnol; 1996 Jan; 44(1-3):193-6. PubMed ID: 8717403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bivalent vaccines against bacterial enteropathogens: construction of live attenuated vaccine strains with two O-serotype specificities.
    Viret JF; Favre D
    Biologicals; 1994 Dec; 22(4):361-72. PubMed ID: 7540016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries.
    Walker RI
    Vaccine; 2005 May; 23(26):3369-85. PubMed ID: 15837361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can a 'flawless' live vector vaccine strain be engineered?
    Galen JE; Levine MM
    Trends Microbiol; 2001 Aug; 9(8):372-6. PubMed ID: 11514219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.